(NASDAQ: CCCC) C4 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.26%.
C4 Therapeutics's earnings in 2026 is -$104,994,000.On average, 10 Wall Street analysts forecast CCCC's earnings for 2026 to be -$122,294,727, with the lowest CCCC earnings forecast at -$182,646,828, and the highest CCCC earnings forecast at -$79,916,525. On average, 9 Wall Street analysts forecast CCCC's earnings for 2027 to be -$103,510,928, with the lowest CCCC earnings forecast at -$129,095,926, and the highest CCCC earnings forecast at -$69,670,817.
In 2028, CCCC is forecast to generate -$95,265,572 in earnings, with the lowest earnings forecast at -$159,696,441 and the highest earnings forecast at $16,393,133.